David Kekich - Stem Cell Therapy Breakthrough
Centagen is developing technology to help millions of people who suffer from chronic pain, disease and injury with an advanced form of adult stem cell therapy. For more information go to http://www.indiegogo.comFrom:CentagenViews:325 118ratingsTime:02:35More inScience Technology
Follow this link:
David Kekich - Stem Cell Therapy Breakthrough - Video
What Areas of Arthritis Do Autologous Stem Cells Work Best For?
What types of conditions and what types of arthritis are most amenable to autologous stem cell treatment. Some joints do better than others. Why that is is still a matter of conjecture. It #39;s important to realize stem cells don #39;t work for every condition.From:Nathan WeiViews:0 1ratingsTime:02:00More inScience Technology
Here is the original post:
What Areas of Arthritis Do Autologous Stem Cells Work Best For? - Video
Conference explores Deaf identity and genetics - Remark! Deaf News
Remark! Deaf News - The best BSL Deaf News, presented in British Sign Language ( BSL ), for the latest Deaf news go to http://www.remark.uk.com 21st December 2011 Conference explores Deaf identity and genetics Last weekend, Bristol #39;s Centre for Deaf Studies hosted a conference that marked the end of a two year project focusing on genetics and the concept of Deafhood. Deafhood is a culturo-linguistic model that refers to the beliefs and practices of the Deaf community and people who use sign language, as well as their language, culture and history. The concept of Deafhood is the opposite of what is known as the #39;medical model #39; of deafness; that deafness is essentially something that should be fixed. The conference, called #39;Sleepwalking into Eugenics #39; arrived in the midst of a range of developments in deafness research, such as the stem cell treatment that has #39;cured #39; deafness in gerbils, that signals the possibility of deafness being #39;cured #39; in humans in the future. The conference was organised by Paddy Ladd and Steve Emery because they felt that the views of the Deaf community were being ignored in genetic research and to address this, they collected the views of Deaf people in individual interviews and group discussions across the UK. The project also looked at the views of hearing people and examined whether their perspective of Deaf people becomes more positive when they have seen the positive elements of Deaf culture for themselves. To do this, the project used a hearing ...From:RemarkLondonViews:0 0ratingsTime:03:45More inNews Politics
Originally posted here:
Conference explores Deaf identity and genetics - Remark! Deaf News - Video
LA JOLLA, Calif., Nov. 14, 2012 /PRNewswire/ --StemGenex, Inc. -- November is National Alzheimer's Disease Awareness Month and is dedicated to raising the awareness of this neurodegenerative disorder. Alzheimer's currently affects 5 million people in the U.S. and 35 million across the globe, and due to aging populations, this number is growing rapidly.
To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/stemgenex-on-the-forefront-of-adult-stem-cell-based-therapy-for-alzheimers-179326951.html
Currently pharmacological treatments only manage symptoms and offer no cure for the disease. Alternatively, adult stem cells have shown great promise to potentially replace lost or support damaged brain cells due to their remarkable ability of differentiating into many cell types.
StemGenex, a U.S. based company, is pioneering new therapeutic methods for adipose-derived adult stem cells. StemGenex has a major emphasis on Alzheimer's disease and other conditions such as Parkinson's, COPD, Multiple Sclerosis and Type 1 Diabetes. For over 6 years StemGenex has been conducting studies to advance Alzheimer's adult stem cell treatment protocols in efforts to alleviate the disease's symptoms. Some innovations at StemGenex include:
Rita Alexander, the President of StemGenex, says, "We are encouraged and excited with our progress in developing methods and protocols for adipose derived adult stem cell treatments for Alzheimer's disease."
Patients receiving treatment are reporting an alleviation of their symptoms which include:
Interestingly, scientific research studies have suggested that adult stem cells can provide both anti-inflammatory, regenerative functions, and immune-regulating properties, all of which could be neuroprotective. Outside their therapeutic potential are recent findings investigating the effects of adult stem cells on Alzheimer's. Remarkably, in this study the use of adult stem cells derived from humans could regenerate Alzheimer's disease brains of animal models.
We are on the brink of some tremendously exciting discoveries and developments in the use of adult stem cell based-therapies, for the treatment of Alzheimer's disease. Also, since adult stem cells can be isolated from an individual's own fat tissue there are no ethical or religious controversies.
To find out more about stem cell treatments contact StemGenex.
La Jolla Cove Research Center
Read more here:
StemGenex™ on the Forefront of Adult Stem Cell -Based Therapy for Alzheimer's
ALAMEDA, Calif.--(BUSINESS WIRE)--
BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent (LOI) with Geron Corporation. The LOI contains broad terms of a potential transaction through which Geron would contribute to BAC its intellectual property and other assets related to Gerons discontinued human embryonic stem cell programs. BioTime would contribute to BAC $5 million in cash, $30 million of BioTime common shares, warrants to purchase eight (8) million common shares of BioTime at a pre-specified price, rights to use certain human embryonic stem cell lines, and minority stakes in two of BioTimes subsidiaries. In addition, a private investor would invest $5 million in cash in BAC.
Following consummation of the potential transaction, Geron stockholders would receive shares representing 21.4% of the common stock of BAC as well as warrants to purchase 8 million shares of BioTime common stock at a pre-specified price. BioTime would own approximately 71.6%, and a private investor would own approximately 7.0% of the outstanding BAC common stock for their $5 million investment. BioTime would also receive warrants that would enable it to increase its ownership in BAC by approximately 2%, which would reduce the Geron stockholders ownership in BAC to 19.2%. BAC would also be committed to pay to Geron royalties on the sale of products that are commercialized in reliance upon Geron patents acquired by BAC.
The LOI is not a binding agreement to complete the transaction. Consummation of the transaction is necessarily subject to entering into a definitive agreement between the parties containing terms and conditions yet to be negotiated.
Kaye Scholer LLP and Thompson, Welch, Soroko & Gilbert LLP are acting as legal counsel to BioTime in connection with the acquisition of Gerons stem cell assets.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards, the leading human gene database, and is developing an integrated database suite to complement GeneCards that will also include the LifeMap database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap will also market BioTime research products. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.
About BioTime Acquisition Corporation
BioTime Acquisition Corporation is a newly formed wholly owned subsidiary of BioTime, Inc., through which BioTime plans to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.
This communication is not an offer to sell any securities or a solicitation of any vote or approval and BioTime and BAC are not offering to sell, or soliciting an offer to buy, any securities in any state where the offer or sale is not permitted.
Visit link:
BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets
Jonathan Milner, CEO of antibodies hothouse Abcam, has joined other angels in backing an exciting new stem cell company in Cambridge UK.
DefiniGEN is one of the first commercial opportunities to arise in the area of stem cells. The ability to generate stem cells by reprogramming cells from patients skin has revolutionised this area of research.
These cells, known as human induced pluripotent stem cells (hIPSC), can be differentiated into almost any cell type, allowing the opportunity to have a ready source of human cells for testing new therapies.
DefiniGEN has been formed to supply hIPSC-derived cells to the drug discovery and regenerative medicine sectors. The company is based on the research of Dr Ludovic Vallier, Dr Tamir Rashid and Professor Roger Pedersen of the Anne McLaren Laboratory of Regenerative Medicine.
The hIPSC-derived cells produced by DefiniGEN show many of the functional characteristics of primary cells, are highly reproducible and can be made in large quantities, making them ideal for liver toxicity testing, which is a major cause of drug candidate failure.
The universitys enterprise fund has also invested 50k in Inotec AMD a spin-out from the Department of Materials Science & Metallurgy, specialising in the treatment of chronic wounds.
Growing numbers of people, especially the elderly, suffer painful, debilitating wounds for five years or more. The treatment of these wounds consumes up to five per cent of total healthcare budgets.
The company is based on a combination of fuel cell technology developed by Professor Derek Fray and a novel system for distributing oxygen over a chronic wound.
Inotec has developed a portable, rechargeable battery powered oxygen generator about the size of smartphone which provides pure humidified oxygen using its own consumable oxygen delivery web.
As previously reported in Business Weekly, the enterprise fund made the first of its three investments to date in Cambridge CMOS Sensors (CCS) 125k.
The rest is here:
Abcam boss backs stem cell venture
Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine"
The good part about getting older is that we gain some wisdom and patience. The bad part is that our bodies start to wear out. But what if we could revitalize our damaged bits back to a healthy state? Come hear what the field of Regenerative Medicine is striving to achieve, and learn how it all begins with the stem cell. Jill Helms is a professor in Plastic and Reconstructive Surgery in the department of surgery at Stanford University #39;s School of Medicine. This Classes Without Quizzes lecture was filmed on location at Stanford Reunion Homecoming 2012 by the Stanford Alumni Association.From:StanfordAlumniViews:11 0ratingsTime:54:05More inEducation
View post:
Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" - Video
cord blood | Cord Blood Cells - Advantages Of Extracting Stem Cells From Umbilical Cord
http://www.cordbloodrecommendation.com The real treatment takes place when the patient is infused with stem cells, which start producing white blood cells in order to make the amount of white blood cells reach the normal number. The nerve cells are known as the ""substantia nigra. Chronic Myelogenous Leukemia Chronic Lymphocytic Leukemia Juvenile Chronic Myelogenous Leukemia Hunter #39;s Syndrome Tay-Sachs Disease Wolman Disease Lesch-Nyhan Syndrome Osteoporosis Beta Thalassemia Major Samples of twin pregnancies were generally rejected due the low availability of cells. The banking facility helps in making blood donation readily available for transplantation #39;s. Flex blood caching can be lifesavers for your family too. She sought umbilical cord blood stem cell therapy from the private Preventative Medicine Clinic in the Netherlands. Stromal cells are a kind of cells that form bone, cartilage, fat, and fibrous connective tissue. Twenty-five children diagnosed with Krabbe #39;s disease were followed and studied regarding their treatments. The National Cord Blood Program staff at the New York Blood Center performs cord blood collection from the expelled placenta. Red blood cells, white blood cells and platelets develop from these cells. The phenomenon is growing fast and the situation is unclear. The blood needs to be collected within 10 to fifteen minutes of birth which is why arrangements must be made ahead of time. If they are able to grow sufficiently, the new cell will make new blood ...From:loshoteles enmedellinViews:0 0ratingsTime:01:18More inScience Technology
View post:
cord blood | Cord Blood Cells - Advantages Of Extracting Stem Cells From Umbilical Cord - Video
cord blood bank | Cheapest Cord Blood Banking
http://www.cordbloodrecommendation.com Cord blood will be the right answer for some diseases. One case is that of Stephen Sprague who was diagnosed with Chronic Myelogenous Leukemia (CML) in 1995. Once you catalog with a cord blood cache, they forward you a kit, containing all the crucial gear for collecting cord blood, along with instructions for the presence doctor, imparter or attention employees. As a parent, we have a choice. It will be easier to take advantage of these new possibilities if you have your own cord blood available for use. She sought umbilical cord blood stem cell therapy from the private Preventative Medicine Clinic in the Netherlands. Another practical application of storing umbilical cord blood after birth is that it can be used for cardiovascular diseases. Everybody, right from the parents to the obstetrician, and the concerning blood bank has to be ready for storage before the baby is born. Why? Because, they say, a public pool to draw on is considerably larger than having a single source of blood. A courier from the stem cell bank will come and retrieve the collection kit and transport for processing and storage. If you can afford to harvest and store your newborns cord blood by all means does so. Although only about 2 cups of cord blood can be collected from the umbilical cord at birth, this small amount is rich in these early (primitive) cells. The closer the blood relation of the cell donor means the more likely that these cells will be helpful. On ...From:luisantafeViews:0 0ratingsTime:01:18More inScience Technology
Excerpt from:
cord blood bank | Cheapest Cord Blood Banking - Video
umbilical cord blood | Cord Blood - Life Saving Out of the Womb
http://www.cordbloodrecommendation.com The collected blood should be processed by specialists in the laboratory within 48 hours and stored properly. Stems cells are very important. Again, these are not hard and fast numbers but just estimates. This procedure also supplies a rapid chromosome analysis within high levels of accuracy. As we all know that it is rich in Hematopoietic stem cells. Extracting bone marrow is a very painful and difficult procedure, and if you have your own blood, then you do not need to make your family members go through the bone marrow transplant procedure. If your child is able to pass the pre-screening process, the program has been highly regarded and is an excellent, free alternative to private registry. Preserved stem cells are used when the body is in a weakened state from disease or treatments such as chemotherapy. Cord blood stem cell therapy has regenerative characteristics. This kind of disease typically attacks the neurons of the central nervous system in the brain. If they decide to donate to a public facility, there are no storage fees however because of privacy concerns all identification features are removed from that particular storage lot within a few years. How many years can a baby #39;s cord blood be saved?Cord blood banking is a relatively new concept. If they are able to grow sufficiently, the new cell will make new blood cells. If you have stem cells of your child, then you will not even need to find bone marrow donors in case your child isFrom:Implantes DentalesViews:0 0ratingsTime:01:18More inScience Technology
Originally posted here:
umbilical cord blood | Cord Blood - Life Saving Out of the Womb - Video